Authors: Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM.
PMID: 32251768 PMCID: PMC7129059 DOI: 10.1016/j.antiviral.2020.104787
Abstract
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
Keywords: ivermectin, COVID-19
Source: https://pubmed.ncbi.nlm.nih.gov/32251768/
Archive: https://archive.is/FfnRj
